## 1 Introduction
Oral mucosal lesions are frequently observed as coinfections or secondary manifestations, presenting with a wide range of clinical characteristics [1; 2; 3]. MRONJ is a severe condition associated with the use of antiresorptive and antiangiogenic agents and requires timely and careful dental management. MRONJ can develop after invasive interventions involving the jawbone, surgery, and tooth extractions. The first MRONJ case was reported by [PERSON] in 2003 and was linked to the use of palmitronate and zoledronate [4]. MRONJ is characterized by the presence of necrotic bone in the maxillofacial region, which persists for >8 weeks despite appropriate management and is not associated with radiation therapy [5]. MRONJ can be triggered by various risk factors, including the type and duration of antiresorptive drug therapy and method of administration. The risk of developing MRONJ is higher among patients taking intravenous medicationsthan those taking oral medications [6; 7; 8]. Additionally, oral inflammatory conditions, such as periodontitis, peri-implantitis, periapical inflammation, dental procedures (e.g., extractions and implants), and other periodontal treatments performed due to inflammation, are considered risk factors. The incidence of MRONJ is also high in patients with removable dentures and smokers, and it occurs more frequently in the lower jaw. Additionally, women are more prone to developing MRONJ, often due to gender-specific conditions, such as breast cancer and postmenopausal osteoporosis. Malignancies, systemic diseases such as diabetes, and the use of medications such as antiangiogenic agents are additional risk factors for developing MRONJ [9; 10; 11; 12]. Hyperglycemia has become a significant healthcare and social issue, particularly in developed industrial societies. It is considered a prevalent condition [12], and dentists must understand its dental implications. The periodontium, alveolar process, and microcirculation are particularly vulnerable to damage due to hyperglycemia [13; 14]. Diabetes increases the risk and severity of periodontitis, which can negatively affect glycemic control in individuals with diabetes mellitus. This two-way relationship highlights how managing one condition can significantly impact the other, indicating the importance of integrated healthcare approaches for patients with both periodontitis and diabetes mellitus [15]. Diabetes is a significant risk factor for MRONJ. Previous studies have explored the potential mechanisms linking diabetes to MRONJ and have shown that impaired immune response, delayed wound healing, and altered bone metabolism may contribute to the increased susceptibility of patients with diabetes to developing MRONJ when taking antiresorptive medications [16]. Therefore, careful management of these patients with diabetes is crucial to reducing MRONJ risk. Platelet-rich preparations, including platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), have shown promise in managing MRONJ. PRP and PRF are rich in growth factors that can enhance tissue regeneration and bone healing. In the context of MRONJ, these preparations play a crucial role in promoting healing and reducing symptoms. They contribute to the repair process by stimulating osteoblast proliferation and angiogenesis, which are particularly beneficial for managing MRONJ and improving clinical outcomes. The use of these preparations in the management of MRONJ has been shown to accelerate bone healing and improve patient prognosis [17; 18; 19]. Given the significant changes to dental care brought about by the COVID-19 pandemic, this study aimed to investigate its effects on the management of MRONJ.